Discovery of LT-1339–553 as a Potent RIPK1 Inhibitor for Schistosomiasis-Induced Hepatic Fibrosis

Key Points

• This research aims to identify and characterize LT-1339–553 as an effective RIPK1 inhibitor for treating hepatic fibrosis induced by schistosomiasis.
• Discovered LT-1339–553 as a RIPK1 inhibitor.
• Assessed its efficacy in models of schistosomiasis-induced hepatic fibrosis.
• Analyzed the molecular mechanisms of action.
• LT-1339–553 significantly reduces hepatic fibrosis compared to control.
• Demonstrated increased liver function markers associated with treatment.
• Reduced RIPK1 activity correlates with decreased fibrosis severity.